Characterization CYP1A2, CYP2C9, CYP2C19 and CYP2D6 Polymorphisms Using HRMA in Psychiatry Patients with Schizophrenia and Bipolar Disease for Personalized Medicine.

Yenilmez E. D., Tamam L., Karaytug O., TULİ A.

Combinatorial chemistry & high throughput screening, cilt.21, sa.5, ss.374-380, 2018 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 21 Sayı: 5
  • Basım Tarihi: 2018
  • Doi Numarası: 10.2174/1386207321666180619164726
  • Dergi Adı: Combinatorial chemistry & high throughput screening
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.374-380
  • Anahtar Kelimeler: CYP450 polymorphism, pharmacogenetic, HRMA, schizophrenia, bipolar disease, drug dosage adjustment, DRUG-METABOLIZING-ENZYMES, GENETIC-POLYMORPHISM, CLINICAL-IMPLICATIONS, GENOTYPE FREQUENCIES, AFRICAN POPULATION, CYTOCHROME P4502C9, PHARMACOGENETICS, DIVERSITY, THERAPY, IDENTIFICATION
  • Çukurova Üniversitesi Adresli: Evet

Özet

Background: The interindividual genetic variations in drug metabolizing enzymes effects the impact and toxicity in plenty of drugs.